Abstracts tagged "Anti-citrullinated Protein Autoantibodies (ACPAs)"

Abstract Number: 0813 • ACR Convergence 2021
Improvement in Clinical Disease Activity and Patient-Reported Outcomes After 6 Months of Treatment with Abatacept, Stratified by Line of Therapy, in Patients with RA: Results from a Large, US, National Observational Study
Leslie Harrold¹, Keith Wittstock², Sheila Kelly², Sang Hee Park², Xue Han², Ying Shan¹, Carla Roberts-Toler¹, Nicole Middaugh¹ and Vadim Khaychuk², ¹CorEvitas, LLC, Waltham, MA, ²Bristol Myers Squibb, Princeton, NJ
Background/Purpose: RA is more responsive to treatment in the early stages of disease, and early treatment may lead to better long-term outcomes.1,2 Data on the…
Abstract Number: 0012 • ACR Convergence 2021
A Novel Mechanism Linking Mucosal Bacteria with Autoantibody Responses in RA: Acetylated Bacterial Lysate as a Model Antigen
Mikhail Volkov, Arieke Kampstra, Karin van Schie, Joanneke Kwekkeboom, Tom WJ Huizinga, René Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is characterized by autoantibodies against post-translationally modified proteins (AMPA) such as citrullinated, carbamylated and acetylated proteins. Importantly, these antibodies are highly…
Abstract Number: 1014 • ACR Convergence 2021
Enhanced Expression of Rheumatoid Arthritis Related Autoantibodies Following Airborne Endotoxin Exposure in the Setting of Collagen-Induced Arthritis
Ted Mikuls¹, Rohit Gaurav¹, Geoffrey Thiele¹, Bryant England¹, Madison Wolfe¹, Brianna Shaw¹, Kristina Bailey¹, Amy Nelson¹, Michael Duryee¹, Carlos Hunter¹, Debra Romberger¹, Dana Ascherman² and Jill Poole¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: In addition to inflammatory arthritis, collagen-induced arthritis (CIA) recapitulates cardinal features of rheumatoid arthritis (RA) including autoreactive T cells, peptidyl-arginine deiminase expression, and citrullination…
Abstract Number: 0021 • ACR Convergence 2021
Unique Alterations in Circulating T Peripheral Helper Cells Are Found in Different Ethnic Groups of ACPA+ Individuals Both At-risk for and with Classified RA
Hideto Takada¹, Yuko Okamoto², Yasuhiro Katsumata³, Jennifer Seifert⁴, Kristen Demoruelle⁵, Jill Norris⁶, Kevin Deane⁷, Masayoshi Harigai³ and V. Michael Holers⁸, ¹Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Japan, ²Tokyo Women's Medical University Division of Rheumatology, 10-22 Kawada-cho, Shinjyuku-ku, Tokyo, Japan, ³Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ⁴University of Colorado School of Medicine, Littleton, CO, ⁵University of Colorado Anschutz Medical Campus, Aurora, CO, ⁶Colorado School of Public Health, Aurora, CO, ⁷University of Colorado Denver, Denver, CO, ⁸University of Colorado, Denver, CO
Background/Purpose: Production of autoantibodies following pathogenic T and B cell interactions precede the development of RA. T follicular helper (Tfh) cells and T peripheral helper…
Abstract Number: 1214 • ACR Convergence 2021
Examining the Relationship Between Shared Epitope, ACPA Seropositivity, and Real-World Drug Effectiveness in Patients with Rheumatoid Arthritis
Kristin Wipfler¹, Joshua Baker², Harlan Sayles³, Xue Han⁴, Sang Hee Park⁴, Keith Wittstock⁴, Ted Mikuls³ and Kaleb Michaud³, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³University of Nebraska Medical Center, Omaha, NE, ⁴Bristol Myers Squibb, Princeton, NJ
Background/Purpose: The shared epitope (SE) is an amino acid sequence motif coded by several HLA-DRB1 alleles that are overrepresented among people with rheumatoid arthritis (RA).…
Abstract Number: 0033 • ACR Convergence 2021
Impaired Adipose Tissue Function in Rheumatoid Arthritis: Association with Autoimmunity, Disease Activity and Therapeutic Response
Iván Arias de la Rosa¹, alejandro Escudero², Cristobal Román-Rodriguez², Rocio Guzmán-Ruiz², Maria del Mar Malagón², Carlos Pérez-Sánchez³, Chamaida Plasencia-Rodríguez⁴, Ana Martinez-Feito⁵, Maria del Carmen Ábalos-Aguilera², Alejandra Patiño-Trives⁶, Jerusalem Calvo², Rafaela Ortega², Eduardo Collantes-Estevez², Chary Lopez-Pedrera² and Nuria Barbarroja¹, ¹University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ³IMIBIC, Córdoba, Spain, ⁴Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Rheumatology, La Paz University Hospital, Madrid, Spain, ⁵ImmunoRheumatology Department, IDIPAZ, Madrid, Spain, ⁶Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain
Background/Purpose: 1) to evaluate the relationship among adipose tissue dysfunction, autoimmunity and disease activity in rheumatoid arthritis (RA) patients; 2) to analyze the direct effect…
Abstract Number: 1243 • ACR Convergence 2021
Real World Validation of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis: Analysis from the RISE Registry
Huifeng Yun¹, Jeffrey Curtis², Lang Chen³, cassie Clinton³, Hubert van Hoogstraten⁴, Stefano Fiore⁴, Markus Rehberg⁵ and Ernest Choy⁶, ¹University of Alabama Birmingham, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Sanofi, Bridgewater, NJ, ⁵Sanofi, Franfurt, Germany, ⁶CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: Accurately identifying patients who may respond better to a specific drug or mechanism of action could improve rational selection of medications to optimize clinical…
Abstract Number: 0034 • ACR Convergence 2021
Immune Complexes Contain Novel Acetylated Antigens in the Synovial Fluid of RA Patients
Khetam Ghannam¹, Holger Bang², Thomas Häupl¹, Eugen Feist³ and Gerd Burmester⁴, ¹Charite University Medicine Berlin, Berlin, Germany, ²Orgentec Diagnostika GmbH, Mainz, Germany, Mainz, Germany, ³Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ⁴Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by genetic predisposition and associated immunological features including the production of autoantibodies against various epitopes. Several…
Abstract Number: 1648 • ACR Convergence 2021
Increasing Rates of Positivity of Autoantibodies Indicates a Shorter Time-to-Diagnosis of Future Rheumatoid Arthritis
Dylan Bergstedt¹, Ryan Peterson², Marie Feser¹, LauraKay Moss¹, Geoffrey Thiele³, Ted Mikuls³, Jess Edison⁴, V. Michael Holers¹ and Kevin Deane⁵, ¹University of Colorado Denver, Aurora, CO, ²Colorado School of Public Health, Aurora, CO, ³University of Nebraska Medical Center, Omaha, NE, ⁴Walter Reed National Military Medical Center, Bethesda, MD, ⁵University of Colorado Denver, Denver, CO
Background/Purpose: Rheumatoid arthritis (RA) has a ‘pre-RA’ period that can be defined by elevations in autoantibodies to citrullinated protein antigens (ACPA) and rheumatoid factor (RF)…
Abstract Number: 0037 • ACR Convergence 2021
Identification and Validation of Four Circulating Autoantibodies Associated with the ACPA Status in Early Rheumatoid Arthritis
Lucía Lourido¹, Cristina Ruiz-Romero², Lidia Collado¹, Monika Hansson³, Lars Klareskog⁴, Ronald Sjöberg⁵, Elisa Pin⁵, Peter Nilsson⁵ and Francisco Blanco-García⁶, ¹Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España., A Coruña, Spain, ²Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). Av. Monforte de Lemos, 3-5. Pabellón 11, 28029, Madrid, España., A Coruña, Spain, ³Division for Rheumatology, Karolinska Institutet, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology & SciLifeLab, Stockholm, Sweden, ⁶Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Universidade da Coruña (UDC), Grupo de Investigación de Reumatología y Salud (GIR-S). Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Fisioterapia, Campus de Oza, 15008, A Coruña, España., A Coruña, Spain
Background/Purpose: The presence of anti-citrullinated protein antibodies (ACPAs) is a highly specific hallmark of rheumatoid arthritis (RA), that is present also in early disease. However,…
Abstract Number: 1652 • ACR Convergence 2021
Symptom Burden in Anti-citrullinated Protein Antibody Positive Individuals At-risk for Rheumatoid Arthritis Is Changing over Time and Comparable to Patients with Early Rheumatoid Arthritis
Paul Studenic¹, Alexandra Circiumaru², Daniel Aletaha³, Katerina Chatzidionysiou⁴, Anca Catrina⁵ and Aase Haj Hensvold⁶, ¹Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, ²Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden, ³Medical University Vienna, Vienna, Austria, ⁴Karolinska Institute, Division of Rheumatology; & Karolinska University Hospital, Rheumatology Unit, Stockholm, Sweden, ⁵Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁶Karolinska Institutet, Division for Rheumatology; & Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden
Background/Purpose: Symptom burden in individuals at risk for developing rheumatoid arthritis (RA) - positive for anti-citrullinated peptide antibodies (ACPA) and musculoskeletal complaints - has not…
Abstract Number: 0038 • ACR Convergence 2021
Arthritis Progression in at Risk Individuals Is Associated with ACPAs Not AMPAs
Alexandra Circiumaru¹, Yogan Kisten², Monika Hansson², Heidi Wähämaa³, Meng Sun³, Vijay Joshua³, Hamed Rezaei⁴, Erik Af Klint⁴, Aleksandra Antovic¹, Anca Catrina³ and Aase Haj Hensvold⁵, ¹Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden, ²Division for Rheumatology, Karolinska Institutet, Stockholm, Sweden, ³Karolinska Institutet and Karolinska university Hospital, Stockholm, Sweden, ⁴Division for Rheumatology, Karolinska Institutet; Department of Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ⁵Karolinska Institutet, Division for Rheumatology; & Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden
Background/Purpose: Individuals with anti citrullinated protein antibodies (ACPA) and musculoskeletal complaints are at high risk for developing rheumatoid arthritis (RA) and often seek medical attention…
Abstract Number: 1654 • ACR Convergence 2021
Comparative Characteristics of the Natural Course of Early Rheumatoid Arthritis with Onset at a Young Age (18-49 Years) and Older (50 Years and Older) Patients Who Did Not Take DMARDs, Biologics, Other Targeted Drugs, Corticoids According to the Russian Register of Arthritis OREL
Azamat Satybaldyev, Galina Gridneva, Anna Misiyuk, Natalia Demidova, Kamalia Kasumova and Evgeny Nasonov, V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia
Background/Purpose: Comparison of frequency of different clinical features of the natural course at the stage of early rheumatoid arthritis (RA) in patients with young and…
Abstract Number: 0039 • ACR Convergence 2021
Elevated IgA Subclass Levels in Rheumatoid Arthritis Patients: Indications of a Mucosal Origin?
Veerle Derksen, Cornelia F. Allaart, Annette H.M van der Helm-van Mil, Tom WJ Huizinga, René Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Mucosal surfaces may be involved in the pathophysiology of rheumatoid arthritis (RA) (1). IgA is the most abundant class of immunoglobulin at mucosal sites…
Abstract Number: 0042 • ACR Convergence 2021
High-throughput Testing for Modified-protein Antibodies in Patients Diagnosed with “Seronegative” Rheumatoid Arthritis
Michael Richter¹, Hari Krishnamurthy², Sylvia Posso³, Jeffrey Carlin⁴ and Jane Buckner³, ¹University of Washington, Mercer Island, WA, ²Vibrant Sciences, San Carlos, CA, ³Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁴Virginia Mason Medical Center, Seattle, WA
Background/Purpose: Antibodies to citrullinated and other modified proteins play a critical role in the pathogenesis of rheumatoid arthritis (RA). The prevalence and degree of multi-site…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].